Cargando…
Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study
OBJECTIVE: To evaluate the efficacy and safety of intramuscular ultra-high-dose methylcobalamin in patients with amyotrophic lateral sclerosis (ALS). METHODS: 373 patients with ALS (El Escorial definite or probable; laboratory-supported probable; duration ≤36 months) were randomly assigned to placeb...
Autores principales: | Kaji, Ryuji, Imai, Takashi, Iwasaki, Yasuo, Okamoto, Koichi, Nakagawa, Masanori, Ohashi, Yasuo, Takase, Takao, Hanada, Takahisa, Shimizu, Hiroki, Tashiro, Kunio, Kuzuhara, Shigeki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581107/ https://www.ncbi.nlm.nih.gov/pubmed/30636701 http://dx.doi.org/10.1136/jnnp-2018-319294 |
Ejemplares similares
-
Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
por: Al-Chalabi, Ammar, et al.
Publicado: (2021) -
Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis
por: Dreger, Marie, et al.
Publicado: (2022) -
Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials
por: van Eijk, Ruben P A, et al.
Publicado: (2018) -
Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials
por: van Eijk, Ruben P A, et al.
Publicado: (2019) -
Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study
por: Lauria, Giuseppe, et al.
Publicado: (2015)